Home/Pipeline/AGI-134

AGI-134

Solid Tumors

Phase 1/2aActive/Uncertain

Key Facts

Indication

Solid Tumors

Phase

Phase 1/2a

Status

Active/Uncertain

Company

BioLineRx

About BioLineRx

BioLineRx is an Israeli biopharmaceutical company dedicated to identifying, in-licensing, and developing promising therapeutic candidates, primarily in oncology. Its strategic focus is on advancing motixafortide, which has demonstrated potential in multiple clinical settings, including as a stem cell mobilizer for autologous transplantation and as a combination therapy for metastatic pancreatic cancer. The company leverages a lean operational model to advance its pipeline through clinical development and strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Hematology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active